303137-57-7

Upstream product

• 606-83-7 3,3-Diphenylpropionic acid 
• 55-81-2 4-Methoxyphenethylamine 

Downstream Products

• 1027234-57-6 6-Amino-hexanoic acid (3,3-diphenyl-propyl)-[2-(4-hydroxy-phenyl)-ethyl]-amide 
• 1028284-31-2 5-Amino-pentanoic acid (3,3-diphenyl-propyl)-[2-(4-hydroxy-phenyl)-ethyl]-amide 
• 1026445-54-4 4-Amino-N-(3,3-diphenyl-propyl)-N-[2-(4-hydroxy-phenyl)-ethyl]-butyramide 

Relevant academic research and scientific papers

Antioxidant activity of diphenylpropionamide derivatives: Synthesis, biological evaluation and computational analysis

We report the synthesis, antioxidant and antiproliferative activity and a QSAR analysis of synthetic diphenylpropionamide derivatives. Synthesis of these compounds was achieved by direct condensation of 2,2- and 3,3-diphenylpropionic acid and appropriate

Synthesis and neuropeptide Y Y1 receptor antagonistic activity of N,N-disubstituted ω-guanidino- and ω-aminoalkanoic acid amides

Patent arpromidine-type histamine H2 receptor agonists such as BU-E-76 (He 90481) were among the first non-peptides reported to display weak neuropeptide Y (NPY) Y1 receptor antagonist activity. In search of new chemical leads for the development of more potent NPY antagonists, a series of N,N-disubstituted ω-guanidino and ω-aminoalkanoic acid amides were synthesized on the basis of structure-activity relationships and molecular modeling studies of arpromidine and related imidazolylpropylguanidines. In one group of compounds the imidazole ring was retained whereas in the second group it was replaced with a phenol group representing a putative mimic of Tyr36 in NPY. Although the substitution patterns have not yet been optimized, the title compounds are NPY Y1 antagonists in human erythroleukemia (HEL) cells (Ca2+ assay) achieving pK(B) values in the range of 6.3-6.6. For representative new substances tested in the isolated guinea pig right atrium histamine H2 receptor agonism could not be found. In the N-(diphenylalkyl)amide series, compounds with a trimethylene chain were more active Y1 antagonists than the ethylene homologs. Concerning the spacer in the ω-amino or ω-guanidinoalkanoyl portion, the best activity was found in compounds with a four- or five-membered alkyl chain or a 1,4-cyclohexylene group. Surprisingly, in contrast to the phenol series, in the imidazole series the compounds with a side chain amino group turned out to be considerably mere potent than the corresponding strongly basic guanidines. Thus, the structure-activity relationships appear to be different for the diphenylalkylamide NPY antagonists with one or two basic groups.